Evofem Biosciences, Inc., held its 2025 Annual Meeting of Stockholders on November 26, 2025. The Consolidated Notice of Meeting, Proxy Statement and Annual Report is available on form 10-K (click here).
Of the Company's 268,232,641 eligible votes as of the "Record Date" for the Annual Meeting, 213,227,083 votes were represented by proxy or in person (approximately 79.5% of the total eligible votes). This constituted a quorum for the purposes of the Annual Meeting.
At this meeting, the Company’s stockholders:
- Elected each of the four nominees as Class I or Class II directors of the Company;
- Approved the proposal on the compensation of Evofem's named executive officers (“Say-on-Pay”);
- Approved the Evofem Biosciences, Inc. 2025 Equity Incentive Plan;
- Approved Proposal 4, thereby authorizing an amendment to the Company’s Certificate of Incorporation to authorize a reverse stock split of the outstanding Common Stock by a ratio of not less than 1-for-500 and no more than 1-for-1,500, with the exact range to be set a whole number within such range by the Board, in its sole discretion, at any time prior to November 26, 2026; and,
- Ratified the appointment of BPM LLP as the Company’s Independent Registered Public Accounting firm for the year ending December 31, 2025.
More detail, including the number of votes cast for, against, withheld, and broker non-votes with respect to each proposal, is included in the Form 8-K (click here).